Technical Field
[0001] The present invention relates to an adult T cell leukemia model animal. More particularly,
the present invention relates to an adult T cell leukemia model animal that allows
human T cell leukemia virus 1 to be proliferated for a long period of time, and allows
detailed analysis of tumorigenesis process as well as tumorigenesis mechanism of adult
T cell leukemia and immune response mechanisms of infected patients against leukemia.
Technical Field
[0002] Adult T cell leukemia (ATL) is a tumor of T cells induced by infection with human
T cell leukemia virus-1 (HTLV-1).
[0003] Many mechanisms from infection of HTLV-1 to tumorigenesis, and development of disease
conditions have not known yet. For example, no specific base sequences that characterize
individual disease conditions have been found even by comparing viral base sequences
in a variety of disease groups. Consequently, it has been supposed that the primary
factor for determining various disease conditions in ATL is ascribed to factors of
the infected patient (host).
[0004] Since the disease conditions in ATL range from acute to chronic syndromes with mild
to acute progress, it is suggested that onset of ATL involves several steps. The multi-step
development of the disease in HTLV-1 infection is conjectured to be affected not only
by the effect of spontaneously occurring mutation but also by the interaction between
proliferation ability of the virus infected cells and immune response of the host
against the virus.
[0005] Since the factors in host is strongly related to onset of ATL by HTLV-1 infection,
a proper animal model is essential for solving the onset mechanism of ATL while effectively
developing preventive, diagnostic and therapeutic methods.
[0006] The HTLV-1 infected cells using cultured cells have been established in ape, feline,
rat and rabbit lymphocytes (Int. J. Cancer, 38:867-875, 1986; Int. J. Cancer 34:513-517,
1984; Jpn. J. Cancer Res., 76:86-94, 1985). HTLV-1 is also known to infect rabbit,
ape and rat (Jpn. J. Cancer res., 76:86-94, 1985; Lab. Invest., 69:336-339, 1993;
Int. J. Cancer, 40:403-407, 1987; J. Vilol., 66:6686-6694, 1992). Several animal models
have been established using these sensitive animals for investigating the diseases
related to HTLV-1. For example, a disease model animal using a WKA rat strain is often
used for investigating pathological mechanisms of HAM/TSP related diseases (J. Exp.
Med., 176:981-989, 1992; J. Vilol., 68:7221-7226, 1994).
[0007] While only a few examples of animal strains using rabbit and rat have been known
as the ATL animal model, on the other hand, the application range thereof is limited.
For example, although adult animals in the rabbit ATL model develop ATL like diseases
with good reproducibility (Lab. Invest., 74:696-710, 1996), no immunological studies
have been carried out in this animal model, mainly because inbred strains of rabbit
can be hardly obtained. Since the ATL like disease are only observed in the neonatal
rat ATL onset model with very short period of the disease duration, it is difficult
to simultaneously perform oncological and immunological studies. It is also impossible
to meet pathological versatility in ATL (J. Vilol., 66:6686-6694, 1992).
[0008] Although establishment of animal models are inevitable for solving the ATL onset
mechanism and effectively developing preventive, diagnostic and therapeutic methods
for the disease, the conventional animal models have not been satisfactory with respect
to their diversely limited application ranges.
[0009] The present invention carried out by taking the foregoing problems into consideration
and the object is to provide novel ATL animal models that can develop the ATL like
diseases with good reproducibility over a long duration time besides permitting oncological
and immunological studies.
Disclosure of Invention
[0010] The present invention for solving the foregoing problems provides an ATL model animal,
which is a T cell function deficient animal transplanted with a HTLV-1 infected cell
line. The HTLV-1 infected cell line is preferably derived from T cells of an animal
having normal immunity, syngeneic to the T cell function deficient animal. It is also
preferable that the T cell function deficient animal is a nude rat.
[0011] The present invention also provides a T cell line FPM1 established by infecting T
cells of rat F344/N Jc1-mu/+ having normal immunity with human T cell leukemia virus-1,
and a T cell line FPM1-V1AX established by proliferating the cell line FPM 1 in the
body of a nude rat F344/N Jcl-rnu/rnu.
Brief Description of the Drawings
[0012]
Fig. 1 is a graph showing subcutaneous proliferation of the cell lines F344-S1 (■)
and TARS-1 (●).
Fig. 2 is a graph showing the tumor growth process in animals transplanted with FPM1-V1AX
alone (■), naive T cells and FPM1-V1AX (○), and immune T cells and FPM1-V1AX (●).
Fig. 3 is a graph showing a specific cytotoxic activity of the T cells from rat having
normal immunity against the HTLV-1 infected T cells. Tha rat is subjected immune induction
by using HTLV-1 tax gene.
Fig. 4 is a graph showing effect of the tax immune T cells on the development of tumors
in the ATL model animal.
Best Mode for Carrying Out the Invention
[0013] The ATL model animal according to the present invention corresponds to an individual
animal established by transplanting a HTLV-1 infected cell line into a T cell function
deficient animal.
[0014] Rats and mice in which syngeneic animal strains have been established may be used
as the objects for the T cell function deficient animal, including the existing nude
rats and nude mice. The animals may be artificially created by knocking-out specific
genes related to the T cell function. In the case of the T cell function deficient
animal being thus artificially created one, wild-type animals thereof may be used
as animals having normal immunity.
[0015] An already established existing cell line may be used for the HTLV-1 infected cell
line, or the cell line may be independently established by infecting the animal cells
with HTLV-1. In vitro or in vivo infection of the animal cells with HTLV-1 is also
possible. When the animal cells are infected in vitro, thymus cells of the animal
are cultivated together with the animal cells infected with HTLV-1.
[0016] The HTLV-1 infected T cell line FPM1 is a novel HTLV-1 infected cell line established
by allowing the T cells of rat F344/N Jcl-rnu/+ having normal immunity to be infected
with the human T cell leukemia virus-1.
[0017] The HTLV-1 infected cell line obtained as described above may be transplanted into
the T cell function deficient animal, and may be subjected to proliferation/subculture
in the animal body. The T cell line FPM1-V1AX according to the present invention is
a novel HTLV-1 infected cell line established by proliferating the T cell line FPM
in body of the nude rat F344/N Jc1-rnu/rnu.
[0018] Then, the HTLV-1 infected cell line is subjected to subcutaneous, intraperitoneal
or intravenous transplantation into the T cell function deficient animals. The T cell
function deficient animal may be an adult or a neonata (for example within 24 hours
after the birth). The number of transplanted cells may be adjusted to 10
4 to 10
8 cells depending on the species and weight of the animal to be transplanted.
[0019] The animal transplanted with the HTLV-1 infected T cell line can proliferate the
HTLV-1 infected T cell line in the for a long period of time, and continues to produce
HTLV-1 products. Accordingly, it becomes possible to precisely analyze the tumorigenesis
process as well as tumorigenesis mechanism of ATL and immunological response mechanism
of the host against the tumor.
[0020] While the present invention is described in more detail with reference to the Examples,
the present invention is by no means restricted to the Examples as set forth below.
EXAMPLE 1: Transplantation of HTLV-1 infected cell line
[0021] Various existing HTLV-1 infected cell lines (2 x 10
6 cells) were subcutaneously or intraperitoneally transplanted into neonatal rats (within
24 hours after the birth). The same cell lines (10 x 10
7) were also subcutaneously, intraperitoneally or intravenously transplanted into the
rats of age four week.
[0022] The HTLV-1 infected cell lines used were a lymphocyte cell line TARS-1 and TART-1
derived from WKA rats (J. Exp. Med., 176:981-989, 1992), a lymphocyte cell line F344-S1
derived from F344 rats (J. Exp. Med., 159:1105-1116, 1984), a HTLV-1 infected cell
line W7TM-1 derived from WKA rats (J. Immunol., 144:4202-4211, 1990), and a HTLV-1
infected human cell line MT2 (Nature, 294:770-771, 1981).
[0023] The rats used were female F344/N Jcl-rnu/rnu nude rats (nu/nu) and F344/N Jcl-mu/+
(nu/+) rats belonging to the same strain as the rats above (both of which were purchased
from Clea Japan Co.), and female F344/S1c (F344) rats and WKA/KmS1c (WKA) rats (both
of which were purchased from SLC Japan Co.).
[0024] The cell line transplanted animals prepared as described above were subjected to
the following tests.
Procedures:
(1) Measurements of subcutaneously transplanted cell line
[0025] After the transplantation, the largest surface lengths of the subcutaneous cancer
(a, mm) and width (b, mm) were measured once a week, and the dimension of the cancer
was calculated by the following equation (Cancer Immunol. Immunother., 44:204-210,
1997).

(2) Histological tests of the cell lined transplanted animal
[0026] Ten week after the transplantation, organs of the animal were sampled and were observed
under a microscope. After fixing the organs with formalin and embedding in paraffin,
sliced specimens were stained with hematoxylin-eosin for microscopic observation.
The frozen slice was immunohistologically stained using primary antibodies such as
a monoclonal antibody against an anti-rat IL-2 receptor α-chain, anti-rat CD4 mAb
or an anti-HTLV-1 Tax mAb (LT-4) (Jan. J. Cancer Res., 81:225-231, 1990).
(3) Detection of HTLV-1 provirus
[0027] Genomic DNAs were isolated from the organs of the transplanted animal, and the px
region of the HTLV-1 provirus was amplified by PCR following the method described
in the literature (J. Vilol., 72:7289-7293, 1998). The genome was also subjected to
reverse PCR to specify the chain sequence of 3'-teminus side of provirus following
the method described in the literature (Blood, 84:3080-3085, 1994).
[0028] Sequences of PCR products were determined using a commercially available sequencer.
Results:
(1) in vivo proliferation of HTLV-1 infected cells
[0029] Table 1 shows the results of microscopic observations of the HTLV-1 infected cell
line, rats transplanted with the cell line, transplantation pathway and each organ.
[0030] As shown in Table 1, the cell lines F344-S 1 and TARS-1 generally proliferated in
the nude rat (nu/nu) irrespective of the transplantation pathway. Fig. 1 shows the
graph showing the subcutaneous proliferation of the cell lines F344-S1 (■) and TARS-1
(●).
[0031] Of the five rats transplanted with F344-S1, three died three week after transplantation.
The remaining four were allowed to commit euthanasia 3, 4, 7 and 8 weeks after transplantation
since they were extremely debilitated. One of these rats developed dysbasia, and others
expressed severe jaundice. The rats transplanted with the cell line TARS-1 survived,
on the other hand, 10 week after transplantation.
[0032] The results of autopsy revealed that the degree of proliferation of the transplanted
cells was the largest in the nude rat lacking the T cell function. However, the cell
lines F344-S1 and TARS-1 did not proliferate in the rat of normal immunity. As shown
in Table 1, TART-1, W7TM-1 and MT-2 did not proliferate in the nude rat as well as
in the animals of normal immunity.

(2) Tumor metastasis in adult nude rat
[0033] Nodes of tumor were observed in the lung, liver, spleen, spinal code, ovary and lymph
node from the results of autopsy of the rats transplanted with the F344-S1 cell line.
Histological inspection showed large infiltration of the tumor cells in the lung,
lymph node and subcutaneous layer. No metastasis of the tumor was observed, on the
other hand, in the rats transplanted with TARS-1, except one rat that showed metastasis
to the lung.
(3) Distribution of provirus HTLV-1 in the tissue
[0034] Table 2 shows the results of analysis in which distribution of the provirus in the
tissue of the nude rat transplanted with the cell lines F344-S1 and TARS-1 was analyzed
by PCR. It is clear from Table 2 that HTLV-1 proviral DNA was detected in almost all
the inspected tissues in all the rats transplanted with F344-S1. The proviral DNA
was also detected in almost all the tissues inspected, although it was not found in
all the rats transplanted with TARS-1. It was confirmed from the results in (2) that
HTLV-1 has been distributed in the tissues in which apparent metastasis has not been
apparent.

EXAMPLE 2: Establishment of HTLV-1 infected T cell line FPM1 and transplantation thereof
into rat
[0035] Spleen cells of rat F344/N Jcl-rnu/+nu/+ were cultivated together with HTLV-1 infected
human cell line MT-2 in a RPMI1640 medium (containing FCS, penicillin, streptomycin;
10 U/ml of interleukin 2 was added at initiation of culture) to establish the HTLV-1
infected T cell line FPM1. This cell line FPM1 expresses CD4, CD5, CD25, MHC-1 and
MHC-II as the cells of the human ATL patient do.
[0036] The established HTLV-1 infected T cell line FPM-1 was cultivated in a RPMI1640 medium
(containing 10% FCS and antibiotics).
[0037] The cell line FPM1 (1 × 10
7 cells) was subcutaneously transplanted in the 4-week-old rats. The cell line FPM1
(2 × 10
6 cells) was also subcutaneously transplanted in neonatal rats (within 24 hours after
the birth).
[0038] While growth of the subcutaneous tumor was observed in two week after the first transplantation
in the 4-week old nude rat received subcutaneous transplantation of FPM1, the cancer
was gradually shrunk and finally disappeared. No evident metastasis was also observed.
However, since HTLV-1 proviral DNA was detected in many tissues by PCR using the genomic
DNA of each tissue as a template as shown in Table 2, it was confirmed that the cell
line FPM1 was transferred into various tissues even when apparent metastasis had not
been observed.
[0039] Increase of tumors was also observed, on the other hand, for a period of two weeks
in the neonatal nude rats transplanted with FPM1. The rats were allowed to commit
euthanasia thereafter since they were extremely debilitated. The immunohistological
inspection revealed that infiltrating tumor cells evidently expresses IL-2 receptor.
The rat CD4 and HTLV-1 tax were also slightly positive in these tumor cells. No tumor
cells were observed at all in the neonate rat of normal immunity transplanted with
FPM1.
EXAMPLE 3: Establishment of HTLV-1 infected T cell line FPM1-V1AX and transplantation
into rat
[0040] FPM1 cells proliferated in the natal nude rat were isolated to establish the cell
line FPM1-N2. The cell line was then subcutaneously transplanted into the natal nude
rat (nu/nu) and the syngeneic rat (nu/+) thereof having mormal immunity. Although
the transplanted cells did not proliferate in the rats of normal immunity (five rats),
the transplanted cells proliferated in the four nude rats. Three of these rats died
two week after the transplantation, and the remaining one was allowed to commit euthanasia.
Thickening of the lymph node was observed by autopsy. The thickened cells were isolated,
and were cultivated to establish the cell line FPM1-V1AX. The results are shown in
Table 3.

[0041] Subsequently, the cell line FPM1-V1AX was intraperitoneally transplanted into three
adult nude rats, confirming that the tumor was grown in all the three rats. One of
the three rats died two week after the transplantation, and the remaining two were
allowed to commit euthanasia three weeks later. The results of autopsy showed metastasis
of the tumor into the liver and thickening of the lymph node in all three rats. Metastasis
into the kidney and spleen was also observed in one rat.
[0042] T cells of the rat of normal immunity (age four week) immunized with the FPM1 cell
line established in Example 2 were intraperitoneally administered to the adult nude
rats with simultaneous subcutaneous transplantation of FPM1-V1AX. The results are
shown in Fig. 2. The subcutaneous tumor continued to grow until two week after the
transplantation in the animals transplanted with FPM1-V1AX alone (■) and with naive
T cells and FPM1-V1AX (○), the tumor contracted in the animal transplanted with the
immune T cells and FPM1-V1AX (●). No metastasis of the tumor was observed in the animals
in which the tumor contracted. In the control animals, on the other hand, metastasis
of the tumor into the lung and liver was observed.
[0043] It was confirmed from these results that the T cell immune system is greatly involved
for inhibiting proliferation of the tumor.
EXAMPLE 4: Induced T-ell immunity by HTLV-1 tax gene
[0044] The HTLV-1 tax expression plasmid and control plasmid were administered to hetero-rats
of normal immunity once a week for successive two weeks using a gene gun. T cells
were isolated one week after the final administration. These T cells were stimulated
with FPM1-V1AX for one week, followed by measurement of cytotoxic activity against
FPM1-V1AX and FPM-SV.
[0045] The results are shown in Fig. 3. Only the T cells derived from the rats administered
with the tax expression plasmid showed the cytotoxic activity specific to the HTLV-1
infected cells.
Example 5: Effect of the tax immunized T cells on the ATL model animal
[0046] FPM1-V1AX was subcutaneously transplanted into nude rats transplanted with T cells
derived from the tax expression plasmid administered rats prepared in Example 4, and
with T cells derived from control plasmid administered rats, respectively, and into
nude rats not transpalnted with the T cells. The size of each subcutaneous cancer
was measured for assessing growth of the tumor.
[0047] The results are shown in Fig. 4. It was confirmed that the T cells derived from the
rats administered with the tax expression plasmid strongly suppress in vivo proliferation
of the HTLV- infected cells.
Industrial Applicability
[0048] The present invention provides an ATL model animal that allows the HTLV-1 infected
cell line to proliferate in vivo over a long period of time. This model animal enables
not only the tumorigenesis process but also the mechanism of onset of ATL and immune
response mechanism of the host against ATL to be precisely analyzed.